S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

Bibliographic Details
Main Authors:	Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J Luck, Daniela Weber, Isabelle Schneider, Andrea Corbacioglu, Verena I Gaidzik, Ekaterina Jahn, Nikolaus Jahn, Silke Kapp-Schwoerer, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S Götze, Thomas Kindler, Michael Lübbert, Richard F Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967452.29390.a8

Similar Items

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
by: Sibylle Cocciardi, et al.
Published: (2019-05-01)

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
by: F. G. Ruecker, et al.
Published: (2022-06-01)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
by: Verena I. Gaidzik, et al.
Published: (2023-05-01)

SEURAT: Visual analytics for the integrated analysis of microarray data
by: Bullinger Lars, et al.
Published: (2010-06-01)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
by: Katherine Kelly, et al.
Published: (2023-08-01)

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
by: R. F. Schlenk, et al.
Published: (2023-09-01)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
by: Etienne Sollier, et al.
Published: (2023-08-01)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
by: Jonas S. Heitmann, et al.
Published: (2023-08-01)

P456: A LONG READ SEQUENCING AND CRISPR-CAS9 BASED APPROACH FOR RAPID COPY-NUMBER ALTERATION AND STRUCTURAL VARIATION DETECTION IN HEMATOLOGIC MALIGNANCIES
by: J. Schrezenmeier, et al.
Published: (2022-06-01)

Functional Classification of <i>TP53</i> Mutations in Acute Myeloid Leukemia
by: Sayantanee Dutta, et al.
Published: (2020-03-01)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
by: Elizabeth Macintyre, et al.
Published: (2020-06-01)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
by: Ian Edward Gentle, et al.
Published: (2021-07-01)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
by: Maximilian Schmutz, et al.
Published: (2023-10-01)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
by: Ekaterina Jahn, et al.
Published: (2023-08-01)

P394: INSIGHTS INTO PATIENT-DERIVED XENOGRAFT MODELS FOR DEK-NUP214 LEUKEMIA
by: F. Charles Cano, et al.
Published: (2022-06-01)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-03-01)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
by: Gallogly MM, et al.
Published: (2016-04-01)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
by: Yanan Zhai, et al.
Published: (2022-08-01)

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA
by: F. Stegelmann, et al.
Published: (2022-06-01)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
by: Anna Riedel, et al.
Published: (2023-08-01)

Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis
by: Ziad Abuhelwa
Published: (2023-05-01)

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT
by: Cristina Papayannidis, et al.
Published: (2022-10-01)

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT
by: Cristina Papayannidis, et al.
Published: (2022-10-01)

Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin
by: Paul W. Manley
Published: (2019-08-01)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
by: Felicitas Thol, et al.
Published: (2021-06-01)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
by: Lindsey T. Brinton, et al.
Published: (2020-06-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
by: Mehmet Baysal, et al.
Published: (2021-03-01)

Anticancer activity of midostaurin in hormone refractory human prostate cancer DU145 cells
by: Jin-Jun Sun, et al.
Published: (2016-03-01)

The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group
by: Carmelo Gurnari, et al.
Published: (2022-10-01)

VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation.
by: Maya K Sethi, et al.
Published: (2017-01-01)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
by: S. Sucha, et al.
Published: (2022-06-01)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
by: Johannes Lübke, et al.
Published: (2023-08-01)

Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer
by: Cheng-Ta Lai, et al.
Published: (2022-10-01)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
by: Andoni Garitano-Trojaola, et al.
Published: (2021-06-01)

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
by: Gabriel Tremblay, et al.
Published: (2018-10-01)

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells
by: Emma Rörby, et al.
Published: (2021-02-01)

Microscale and Mesoscale Aeolian Processes of Sandy Coastal Foredunes from Background to Extreme Conditions
by: Bianca R. Charbonneau, et al.
Published: (2021-11-01)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
by: A. Reiter, et al.
Published: (2022-06-01)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
by: Shujiao He, et al.
Published: (2022-05-01)

Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin.
by: Salvatore Perrone, et al.
Published: (2020-04-01)